Flow Diversion Aneurysm Market – By Device Type (Pipeline Embolization Device (PED), Silk Flow Diverter, Flow Re-direction Endoluminal Device (FRED), p64 Flow-Modulation Device, Surpass Flow-Diverter), By Aneurysm Type (Unruptured, Fusiform, Dissecting, Saccular, Others), By End-User (Hospitals, Specialty Clinics), By Geography – Global Opportunity Analysis & Industry Forecast, 2024-2030

Flow Diversion Aneurysm Market Overview:

The Flow Diversion Aneurysm Market Size is valued at $8.23 Billion by 2030, and is anticipated to grow at a CAGR of 9% during the forecast period 2024 -2030. The Flow Diversion Aneurysm Market is experiencing significant growth, driven by increasing demand for minimally invasive treatments for cerebral aneurysms. Flow diverter stents, which work by redirecting blood flow away from aneurysms to promote natural healing, have become a preferred choice among healthcare providers due to their efficacy and safety profiles. This market expansion is supported by advancements in medical technology and a growing awareness of neurological disorders. Additionally, the aging population and rising prevalence of hypertension, a major risk factor for aneurysms, further fuel the demand for flow diversion treatments. 

As healthcare infrastructure improves globally, especially in emerging markets, the adoption of these advanced therapeutic solutions is anticipated to rise. Consequently, the flow diversion aneurysm market presents lucrative opportunities for stakeholders, including medical device manufacturers, healthcare providers, and investors, as it addresses a critical need in neurovascular care with innovative and effective treatment options.

Market Snapshot: 

Flow Diversion Aneurysm Market - Report Coverage:

The “Flow Diversion Aneurysm Market Report - Forecast (2024-2030)” by IndustryARC, covers an in-depth analysis of the following segments in the Flow Diversion Aneurysm Market.

COVID-19 / Ukraine Crisis - Impact Analysis:  

• The COVID-19 pandemic significantly affected the Flow Diversion Aneurysm Market by disrupting supply chains, delaying elective procedures, and shifting healthcare priorities. Initially, the market faced substantial setbacks due to postponed treatments and surgeries as healthcare systems focused on managing the pandemic. Supply chain interruptions also contributed to shortages in essential medical devices and materials. However, the market adapted by leveraging telemedicine for pre- and post-operative care, ensuring continuity in patient management. As healthcare systems gradually recovered, there was a resurgence in demand for flow diversion treatments, driven by the backlog of deferred procedures. Moreover, the pandemic accelerated the adoption of digital health technologies, enhancing the efficiency of treatment planning and patient follow-ups. Overall, while COVID-19 posed significant challenges, it also catalyzed innovation and adaptation within the Flow Diversion Aneurysm Market.
• The Russo-Ukraine War has significantly impacted the Flow Diversion Aneurysm Market, primarily through disrupted supply chains and economic instability. The conflict has led to manufacturing slowdowns and logistical challenges, as key medical device components often transit through affected regions. Additionally, economic sanctions and currency fluctuations have increased costs and reduced market accessibility for many companies. Despite these challenges, the market remains resilient, with continued demand driven by the critical nature of aneurysm treatments. Companies are adapting by seeking alternative supply sources and focusing on innovation to maintain market growth. The long-term outlook suggests a gradual recovery as geopolitical tensions stabilize and supply chains reconfigure to mitigate current vulnerabilities.

Key Takeaways:

Treatment of Unruptured Aneurysms is Leading the Market

The growing demand for the flow diversion technique in treating unruptured aneurysms is primarily driven by its potential to reconstruct the diseased parent vessel, offering a minimally invasive alternative to traditional surgical methods. This technique redirects blood flow away from the aneurysm, promoting thrombosis within the aneurysm while preserving normal blood flow in the parent vessel. Recent advancements, such as the introduction of the Tubridge flow diverter in April 2024, have demonstrated improved efficacy and safety, further boosting its adoption [2]. Additionally, standardized evaluation methodologies for flow diverters, as proposed in June 2024, have enhanced clinical outcomes by providing clearer guidelines for their use [1]. The continuous refinement of these devices and their growing acceptance among neurosurgeons underscore the demand for innovative aneurysm treatments that can reduce procedural risks and improve patient outcomes.

Growing Demand for Flow Diversion Technique in Hospital for Treatment of Aneurysms

The demand for the flow diversion technique in treating aneurysms in hospitals is escalating due to its innovative approach in reconstructing the diseased parent vessel and improving patient outcomes. This minimally invasive procedure, which redirects blood flow away from the aneurysm, significantly reduces the risk of rupture and subsequent complications. Hospitals are increasingly adopting this technique, driven by its proven efficacy in accelerating aneurysm occlusion through enhanced flow reduction. Recent advancements in flow diversion technology and the introduction of new devices, as noted in the latest evaluations and product developments, have bolstered its acceptance in clinical settings. The comprehensive benefits, including improved safety profiles and the ability to treat complex aneurysms, make flow diversion a preferred choice among neurosurgeons. The market for this technique is projected to grow significantly, reflecting its critical role in modern aneurysm management and the continuous advancements in medical technology.

Growing Demand for Flow Diversion Aneurysm Treatment Due to Improved Patient Outcomes

The demand for flow diversion aneurysm treatment is increasing significantly due to its ability to enhance patient outcomes by reconstructing diseased parent vessels and reducing the risk of rupture. This minimally invasive technique effectively redirects blood flow away from aneurysms, facilitating quicker and more reliable occlusion. Its adoption in clinical practice is bolstered by recent technological advancements and the introduction of new devices that improve safety and efficacy. Hospitals and neurosurgeons are increasingly favoring flow diversion methods, recognizing their superior performance in treating complex aneurysms and their potential to reduce procedural complications. This growing preference reflects the broader trend towards advanced medical interventions that prioritize patient safety and long-term health benefits.

Negative Impact of High Treatment Costs on Flow Diversion Aneurysm

The high cost of flow diversion treatment for aneurysms presents a significant challenge, limiting its accessibility and adoption among patients and healthcare providers alike. This advanced medical procedure involves expensive devices and specialized expertise, contributing to its overall financial burden. The cost implications often deter patients from opting for this treatment, especially in regions with limited healthcare coverage or high out-of-pocket expenses. Moreover, hospitals face financial constraints in procuring and maintaining flow diversion equipment, affecting their capacity to offer this technology to a broader patient base. Efforts to mitigate these costs through insurance coverage expansion and technological advancements are ongoing, yet the affordability gap remains a critical issue in achieving equitable access to advanced aneurysm care. Addressing these financial barriers is essential for enhancing patient outcomes and ensuring broader healthcare equity in aneurysm treatment.

Key Market Players: 

Product launches, approvals, patents and events, acquisitions, partnerships and collaborations are key strategies adopted by players in the Flow Diversion Aneurysm Market. The top 10 companies in this industry are listed below:

1. Acandis Gmbh 
2. Balt Extrusion 
3. InspireMD
4. Medtronic plc 
5. Terumo Corporation (MicroVention, Inc.) 
6. Phenox Gmbh 
7. Stryker Corporation
8. Endologix LLC 
9. Evasc Medical Systems
10. Siemens Healthineers

Scope of the Report: